Shares of Jade Biosciences, Inc. (NASDAQ:JBIO – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $51.75.
JBIO has been the subject of a number of recent analyst reports. Wedbush lifted their price target on shares of Jade Biosciences from $45.00 to $47.00 and gave the stock an “outperform” rating in a research note on Monday, August 10th. BTIG Research lifted their price objective on Jade Biosciences from $74.00 to $77.00 and gave the company a “buy” rating in a report on Monday, August 10th. Jefferies Financial Group reissued a “buy” rating and set a $48.00 target price on shares of Jade Biosciences in a research report on Tuesday, August 11th. Piper Sandler set a $55.00 price objective on Jade Biosciences in a research note on Tuesday, June 2nd. Finally, Wall Street Zen lowered shares of Jade Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th.
Read Our Latest Stock Report on Jade Biosciences
Institutional Investors Weigh In On Jade Biosciences
Jade Biosciences Price Performance
Shares of Jade Biosciences stock opened at $20.84 on Monday. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -10.85 and a beta of 1.49. Jade Biosciences has a twelve month low of $6.91 and a twelve month high of $28.00. The business has a 50-day moving average price of $21.42 and a 200-day moving average price of $19.21.
Jade Biosciences (NASDAQ:JBIO – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). On average, equities analysts expect that Jade Biosciences will post -2.84 EPS for the current fiscal year.
About Jade Biosciences
Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.
The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.
See Also
- Five stocks we like better than Jade Biosciences
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for Jade Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jade Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
